ENVB — Enveric Biosciences Share Price
0.000.00%
Last trade - 00:00- $4.85m
- -$1.50m
- 18
- 41
- 20
- 15
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.73 | ||
| Price to Tang. Book | 0.75 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -216.99% | ||
| Return on Equity | -179% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 39.91 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders. The Company, through Psybrary has created a robust intellectual property (IP) portfolio of new chemical entities for specific mental health indications. Its lead program, the EVM201 Series, comprises synthetic prodrugs of the active metabolite, psilocin. It is developing the first product from the EVM201 Series, EB-002, for the treatment of psychiatric disorders. The Company is also advancing its second program, the EVM301 Series, EB 003, which is an approach to the treatment of difficult-to-address mental health disorders. Within the Psybrary, it has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). It has created over 1,000 novel psychedelic molecular compounds and derivatives.
Directors
- David Johnson CHM (64)
- Avani Kanubaddi PRE (49)
- Joseph Tucker CEO (53)
- Carter Ward CFO (57)
- Jillian Hagel CTO (43)
- Peter Facchini CSO (58)
- Bob Dagher OTH
- Brad Thompson DRC
- George Kegler IND (64)
- Douglas Lind IND (49)
- Sol Mayer IND (57)
- Marcus Schabacker IND (57)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 28th, 1994
- Public Since
- July 21st, 2009
- No. of Shareholders
- 202
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 7,752,005
- Address
- 4851 Tamiami Trail N, Suite 200, NAPLES, 34103
- Web
- https://www.enveric.com/
- Phone
- +1 2393021707
- Contact
- Daniel Kontoh Boateng
- Auditors
- Marcum LLP
Upcoming Events for ENVB
Enveric Biosciences Inc Annual Shareholders Meeting
Q3 2024 Enveric Biosciences Inc Earnings Release
Similar to ENVB
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Enveric Biosciences share price?
As of Today at 20:31 UTC, shares in Enveric Biosciences are trading at $0.61. This share price information is delayed by 15 minutes.
How has the Enveric Biosciences share price performed this year?
Shares in Enveric Biosciences last closed at $0.61 and the price had moved by -83.83% over the past 365 days. In terms of relative price strength the Enveric Biosciences share price has underperformed the S&P500 Index by -87.14% over the past year.
What are the analyst and broker recommendations for Enveric Biosciences?
The overall consensus recommendation for Enveric Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Enveric Biosciences dividend yield?
Enveric Biosciences does not currently pay a dividend.
Does Enveric Biosciences pay a dividend?
Enveric Biosciences does not currently pay a dividend.
When does Enveric Biosciences next pay dividends?
Enveric Biosciences does not currently pay a dividend.
How do I buy Enveric Biosciences shares?
To buy shares in Enveric Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Enveric Biosciences?
As of the previous close price of $0.61, shares in Enveric Biosciences had a market capitalisation of $4.75m.
Where are Enveric Biosciences shares listed?
Here are the trading details for Enveric Biosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ENVB
What kind of share is Enveric Biosciences?
Based on an overall assessment of its quality, value and momentum Enveric Biosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Enveric Biosciences share price forecast for 2024?
The analyst consensus target price for shares in Enveric Biosciences is $7.88. That is 1186.11% above the last closing price of $0.61.
Analysts covering Enveric Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$1.93 for the next financial year.
What is the trend in the Enveric Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Enveric Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -59.44%.
As of the last closing price of $0.61, shares in Enveric Biosciences were trading -53.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Enveric Biosciences PE Ratio?
The Enveric Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Enveric Biosciences?
Enveric Biosciences' management team is headed by:
- David Johnson - CHM
- Avani Kanubaddi - PRE
- Joseph Tucker - CEO
- Carter Ward - CFO
- Jillian Hagel - CTO
- Peter Facchini - CSO
- Bob Dagher - OTH
- Brad Thompson - DRC
- George Kegler - IND
- Douglas Lind - IND
- Sol Mayer - IND
- Marcus Schabacker - IND